Granulocyte-macrophage colony-stimulating factor and the immune system
10.1007/bf02990841
Crossref journal-article
Springer Science and Business Media LLC
Medical Oncology (297)
Bibliography

Tarr, P. E. (1996). Granulocyte-macrophage colony-stimulating factor and the immune system. Medical Oncology, 13(3), 133–140.

Authors 1
  1. Philip E. Tarr (first)
References 101 Referenced 50
  1. Marty, M. (ed.) (1996)Manual of GM-CSF. Oxford: Blackwell Science. / Manual of GM-CSF (1996)
  2. Jones, T.C. (1994) Future uses of granulocyte-macrophage colony-stimulating factor.Stem Cells 12, Suppl 1, 229–39. (10.1002/stem.5530120719) / Stem Cells by T.C. Jones (1994)
  3. Ruef, C. and Coleman, D.L. (1990) GM-CSF: Pleiotropic cytokine with potential clinical usefulness.Rev. Inf. Dis. 12, 41–62. (10.1093/clinids/12.1.41) / Rev. Inf. Dis. by C. Ruef (1990)
  4. Gasson, J.C. (1991) Molecular physiology of GM-CSF.Blood 11, 1131–45. (10.1182/blood.V77.6.1131.1131) / Blood by J.C. Gasson (1991)
  5. Bos, J.D. and Kapsenberg, ML. (1993) The skin immune system: progress in cutaneous biology.Immunol. Today 14, 75–8. (10.1016/0167-5699(93)90062-P) / Immunol. Today by J.D. Bos (1993)
  6. Matsue, H., Cruz, Jr, P.D., Bergstesser, P.R. and Takashima, A. (1992) Cytokine expression by epidermal cell subpopulations.J. Invest. Dermatol. 99, 42S-45S. (10.1111/1523-1747.ep12668619) / J. Invest. Dermatol. by H. Matsue (1992)
  7. Jung, H.C., Eckmann, L., Yang, S.K. et al. (1995) A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.J. Clin. Invest. 95, 55–65. (10.1172/JCI117676) / J. Clin. Invest. by H.C. Jung (1995)
  8. Broide, D.H., Paine, MM. and Firestein, G.S. (1992) Eosinophils express interleukin-5 and granulocyte-macro- phage colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics.J. Clin. Invest. 90, 1414–24. (10.1172/JCI116008) / J. Clin. Invest. by D.H. Broide (1992)
  9. Kita, H., Ohnishi, T., Okubo, Y., Weiler, D. and Abrams, J.S. (1991) Granulocyte-macrophage colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils.J. Exp. Med. 174, 745–8. (10.1084/jem.174.3.745) / J. Exp. Med. by H. Kita (1991)
  10. Waellert, B., Desreumaux, P., Copin, M.C. et al.(1995) Immunoreactivity for interleukin 3 and 5 and granulocyte-macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma.J. Exp. Med. 182, 1897–1904. (10.1084/jem.182.6.1897) / J. Exp. Med. by B. Waellert (1995)
  11. Schreiber, R.D. and Chaplin, D.D. (1995) Cytokines, inflammation, and innate immunity. In M.M. Frank, K.F. Austen, H.N. Claman and E.R Unanue,Samter’s immunologic diseases, 5th edn, pp. 297–301. Boston: Little, Brown. / Samter’s immunologic diseases by R.D. Schreiber (1995)
  12. Dixon Gray J., Hirokawa, M. and Horwitz, D.A. (1994) The role of TGF/3 in the generation of suppression: An interaction between CD8+ T and NK cells.J. Exp. Med. 180, 1937–42. (10.1084/jem.180.5.1937) / J. Exp. Med. by Gray J. Dixon (1994)
  13. Hogasen, A.K., Hestdal, K., Hogasen, K. and Abrahamsen, T.G. (1995) Transforming growth factor beta modulates C3 and factor B synthesis and complement receptor 3 expression in cultured human monocytes.J. Leuk. Biol. 57, 287–96. (10.1002/jlb.57.2.287) / J. Leuk. Biol. by A.K. Hogasen (1995)
  14. Cassatella, M.A., Meda, L., Bonora, S., Ceska, M. and Constantin, G. (1993) Interleukin-10 (IL-10) inhibits the release of proinflammatory cytokines from polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide.J. Exp. Med. 178, 2207–11. (10.1084/jem.178.6.2207) / J. Exp. Med. by M.A. Cassatella (1993)
  15. Kurzrock, R., Talpaz, M. and Gutterman, J. (1992) Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.Am. J. Med. 93, 41–8. (10.1016/0002-9343(92)90678-5) / Am. J. Med. by R. Kurzrock (1992)
  16. Stewart-Akers, A.M., Cairns, J.S., Tweardy, DJ. and McCarthy, S.A. (1994) GM-CSF augmentation of T cell receptor dependent and T cell receptor independent thymocyte proliferation.Blood 83, 713–23. (10.1182/blood.V83.3.713.713) / Blood by A.M. Stewart-Akers (1994)
  17. Santoli, D., Clark, S.C., Kreider, B.L., Maslin, P.A. and Rovera, G. (1988) Amplification of IL-2 driven T cell proliferation by recombinant human IL-3 and GM-CSF.J. Immunol. 141, 519–26. (10.4049/jimmunol.141.2.519) / J. Immunol. by D. Santoli (1988)
  18. Burgess, A.W., Begley, C.G., Johnson, G.R. et al. (1987) Purification and properties of bacterially synthesized human GM-CSF.Blood 69, 443–51. (10.1182/blood.V69.1.43.43) / Blood by A.W. Burgess (1987)
  19. Tarr, P.E., Lin, R., Mueller, E. A., Kovarik, J.M., Guillaume, M. and Jones, T.C. (1996) Evaluation of tolerability and antibody response after recombinant human granulocyte- macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine.Vaccine,14, 1199–1204. (10.1016/S0264-410X(96)00031-X) / Vaccine by P.E. Tarr (1996)
  20. Estey, E.H., Kurzrock, R., Talpaz, M. et al (1991) Effects of low doses of rhGM-CSF in patients with myelodysplastic syndromes.Br. J. Haematol. 77, 291–5. (10.1111/j.1365-2141.1991.tb08573.x) / Br. J. Haematol. by E.H. Estey (1991)
  21. Jones, T., Stern, A. and Lin, R. (1994) Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant.Eur. J. Clin. Microbiol. Infect. Dis. Suppl. 2, 47S-53S. (10.1007/BF01973602) / Eur. J. Clin. Microbiol. Infect. Dis. Suppl. by T. Jones (1994)
  22. Frenette, P.S. and Wagner, D.D. (1996) Adhesion molecules-part II: Blood vessels and blood cells.N. Engl. J. Med. 335, 43–5. (10.1056/NEJM199607043350108) / N. Engl. J. Med. by P.S. Frenette (1996)
  23. Okahara, H., Yagita, H., Miyzke, K. and Okamura, K. (1994) Involvement of very late activation antigen 4 (VLA-4) and vascular adhesion molecule 1 (VCAM-1) in tumor necrosis factor a enhancement of experimental metastasis.Cancer Res. 54, 3233–6. / Cancer Res. by H. Okahara (1994)
  24. Coleman, D.L., Chodakewitz, J.A., Bartiss, A.H. and Mellors, J. W. (1988) GM-CSF enhances selective effector functions of tissue derived macrophages.Blood 72, 573–8. (10.1182/blood.V72.2.573.573) / Blood by D.L. Coleman (1988)
  25. Smith, P.D., Lamerson, C.L., Saini, S.S., Wahl, L.M., Calderone, R.A. and Wahl, S.M. (1990) Granulocytemacrophage colony-stimulating factor augments human monocyte fungicidal activity forCandida albicans.J. Infect. Dis. 161, 999–1005. (10.1093/infdis/161.5.999) / J. Infect. Dis. by P.D. Smith (1990)
  26. Bermudez, L.E., Martinelli, J., Petrovsky, M., Kolowski, P. and Young, L. (1994) Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibodies against mycobacterium avium complex infection in the beige mouse model.J. Infect. Dis. 169, 575–80. (10.1093/infdis/169.3.575) / J. Infect. Dis. by L.E. Bermudez (1994)
  27. Reed, S.G., Nathan, C.F., Pihl, D.L. et al. (1987) Recombinant granulocyte-macrophage colony-stimulating factor activates macrophages to inhibitTrypanosoma cruzi and release hydrogen peroxide: Comparison with interferon.J. Exp. Med. 166, 1734–46. (10.1084/jem.166.6.1734) / J. Exp. Med. by S.G. Reed (1987)
  28. Bodey, G.P., Anaissie, E., Gutterman, J. and Vadhan-Raj, S. (1993) Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.Clin. Inf. Dis. 17, 705–7. (10.1093/clinids/17.4.705) / Clin. Inf. Dis. by G.P. Bodey (1993)
  29. Badaro, R., Nascimento, C, Carvalho, J. S. et al. (1994) Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis.J. Inf. Dis. 170, 413–8. (10.1093/infdis/170.2.413) / J. Inf. Dis. by R. Badaro (1994)
  30. Senneville, E., Beuscart, C, Morand, P. et al. (1995) Sulfa- diazine-Pyrimethamine (SP) and granulocyte-macrophage colony-stimulating factor vs SP alone as treatment for central nervous toxoplasmosis in AIDS patients (abstract 1225). Prog. Abstr. 35th Intersci. Conf. on antimicrobial agents and chemotherapy, p. 245.San Francisco.
  31. Charak, B.S., Agah, R. and Mazumder, A. (1993) GM-CSF induced ADCC in bone marrow macrophages: Application in bone marrow transplantation.Blood 81, 3474–9. (10.1182/blood.V81.12.3474.3474) / Blood by B.S. Charak (1993)
  32. Kushner, B.H. and Cheung, N.K.V. (1989) GM-CSF enhances 3F8 monoclonal ADCC against human melanoma and neuroblastoma.Blood 73, 1936–41. (10.1182/blood.V73.7.1936.1936) / Blood by B.H. Kushner (1989)
  33. Masucci, G., Wersaell, P., Ragnhammar, P. and Mellstedt, H. (1989) GM-CSF augments the cytotoxic capacity of lymphocytes and monocytes in ADCC.Cancer Immunol. Immunother. 29, 288–92. (10.1007/BF00199217) / Cancer Immunol. Immunother. by G. Masucci (1989)
  34. Connor, R.I., Shen, L. and Fanger, M.W. (1990) Evaluation of the ADCC capabilities of individual human monocytes.J. Immunol 145, 1483–9. (10.4049/jimmunol.145.5.1483) / J. Immunol by R.I. Connor (1990)
  35. Mellstedt, H., Fagerberg, J., Frö’din, J.E., Liljefors, M. and Ragnhammar, P. (1996) Colorectal cancer in section: clinical use in oncology. In M. Marty (ed.),Manual of GM-CSF, pp. 86–95. Oxford: Blackwell Science. / Manual of GM-CSF by H. Mellstedt (1996)
  36. Grabstein, K.H., Urdal, D.L., Tushinski, R.J. et al. (1986) Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.Science 232, 506–8. (10.1126/science.3083507) / Science by K.H. Grabstein (1986)
  37. Kleinerman, E.S., Knowles, R.D., Lachman, L.B. and Gutterman, J. (1988) Effect of recombinant GM-CSF on human monocyte activityin vitro and following intravenous administration.Cancer Res. 48, 2604–9. / Cancer Res. by E.S. Kleinerman (1988)
  38. Grabstein, K.H. and Alderson, M.R. (1993) Regulation of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. In R. Van Furth (ed.),Hemopoietic growth factors and mononuclear phagocytes, pp. 140–7. Basel: Karger. / Hemopoietic growth factors and mononuclear phagocytes by K.H. Grabstein (1993)
  39. Ho, A.D., Haas, R., Wulf, G. et al. (1990) Activation of lymphocytes induced by rhGM-CSF in patients with malignant lymphoma.Blood 75, 203–12. (10.1182/blood.V75.1.203.203) / Blood by A.D. Ho (1990)
  40. Bendall, L.J., Kortlepel, K. and Gottlieb, DJ. (1995) GM- CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1.Leukemia 9, 677–84. / Leukemia by L.J. Bendall (1995)
  41. Scott, P. and Trinchieri, G. (1995) The role of natural killer cells in host-parasite interactions.Curr. Op. Immunol. 7, 34–40. (10.1016/0952-7915(95)80026-3) / Curr. Op. Immunol. by P. Scott (1995)
  42. Miller, J.S., Oelkers, S., Verfaillie, C. and McGlave, P. (1992) Role of monocytes in the expansion of human activated NK cells.Blood 80, 2221–9. (10.1182/blood.V80.9.2221.2221) / Blood by J.S. Miller (1992)
  43. Schuurman, B., Beelen, R.HJ. and Meyer, S. (1996) Adjuvant treatment in surgery: colorectal cancer, in section: future uses. In M. Marty (ed.),Manual of GM-CSF. Oxford: Blackwell Science. / Manual of GM-CSF by B. Schuurman (1996)
  44. Levin, D., Constant, S., Pasqualini, T., Fla veil R. and Bottomly, K. (1993) Role of dendritic cells in the priming of CD4 + T lymphocytes to peptide antigenin vivo.J. Immunol. 151, 6742–50. (10.4049/jimmunol.151.12.6742) / J. Immunol. by D. Levin (1993)
  45. Young, J.W. and Steinman, R.M. (1990) Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper cells.J. Exp. Med. 171, 1315–22. (10.1084/jem.171.4.1315) / J. Exp. Med. by J.W. Young (1990)
  46. Caux, C, Liu, Y.J. and Banchereau, J. (1995) Recent advances in the study of dendritic cells and follicular dendritic cells.Immunol. Today 16, 2–4. (10.1016/0167-5699(95)80061-1) / Immunol. Today by C Caux (1995)
  47. Croft, M. (1994) Activation of naive, memory, and effector T cells.Curr. Op. Immunol 6, 431–7. (10.1016/0952-7915(94)90123-6) / Curr. Op. Immunol by M. Croft (1994)
  48. Berg, S.F.,. Mjaaland, S. and Fossum, S. (1994) Comparing macrophages and dendritic leukocytes as antigen presenting cells from humoral responsesin vivo and by antigen targeting.Eur. J. Immunol. 23, 1262–8. (10.1002/eji.1830240604) / Eur. J. Immunol. by S.F. Berg (1994)
  49. Kaplan, G., Walsh, G., Guido, L. S. et al (1992) Novel responses of human skin to intradermal recombinant granulocyte-macrophage colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.J. Exp. Med. 175, 1717–28. (10.1084/jem.175.6.1717) / J. Exp. Med. by G. Kaplan (1992)
  50. Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble antigen by cultured human Des is maintained by GM-CSF plus IL-4 and downregulated by TNF- α.J. Exp. Med. 179, 1109–18. (10.1084/jem.179.4.1109) / J. Exp. Med. by F. Sallusto (1994)
  51. Caux, C, Dezutter-Dambuyant, C, Schmitt, D. and Banchereau, J. (1992) GM-CSF and TNF-α cooperate in the generation of Langerhans cells.Nature 360, 258–61. (10.1038/360258a0) / Nature by C Caux (1992)
  52. Inaba, K., Inaba, M.; Romani, N. et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF.J. Exp. Med. 176, 1693–1702. (10.1084/jem.176.6.1693) / J. Exp. Med. by K. Inaba (1992)
  53. Marcowicz, S. and Engleman, E. (1990) Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cellsin vitro.J. Clin. Invest. 85, 955–61. (10.1172/JCI114525) / J. Clin. Invest. by S. Marcowicz (1990)
  54. Austyn, J. M. (1996) New Insights into the mobilization and phagocytic activity of dendritic cells.J. Exp. Med. 183, 1287–92. (10.1084/jem.183.4.1287) / J. Exp. Med. by J. M. Austyn (1996)
  55. Fischer, H.G., Frosch, S., Reske, K. and Reske-Kunz, A.B. (1988) Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow culture to synthesis of MHC class II molecules and to augmented antigen presentation function.J. Immunol 141, 3882–8. (10.4049/jimmunol.141.11.3882) / J. Immunol by H.G. Fischer (1988)
  56. Morrissey, P.J., Bressler, L., Park, L.S., Alpert, A. and Gillis, S. (1987) Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen presenting cells.J. Immunol 139, 1113–9. (10.4049/jimmunol.139.4.1113) / J. Immunol by P.J. Morrissey (1987)
  57. Alvaro-Garcia, j.M., Zvaifler, N.J. and Firestein, G.S. (1989) Cytokines in chronic inflammatory arthritis. IV. Granulocyte-macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: A possible role in rheumatoid arthritis.J. Exp. Med. 170, 865–75. (10.1084/jem.170.3.865) / J. Exp. Med. by j.M. Alvaro-Garcia (1989)
  58. Larsen, C.P., Ritchie, S.C., Hendrix, R. et al. (1994) Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression in murine dendritic cells.J. Immunol. 152, 5208–19. (10.4049/jimmunol.152.11.5208) / J. Immunol. by C.P. Larsen (1994)
  59. Mayordomo, J.I., Zorina, T., Storkus, W J. et al. (1995) Bone marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.Nature Med. 1, 1297–1302. (10.1038/nm1295-1297) / Nature Med. by J.I. Mayordomo (1995)
  60. Szabolcs, P., Moore, M.A.S. and Young, J.W. (1995) Expansion of immunostimulatory dendritic cells among myeloid progeny of human cd34+ bone marrow precursors, cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-a.J. Immunol 154, 5851–61. (10.4049/jimmunol.154.11.5851) / J. Immunol by P. Szabolcs (1995)
  61. Porcelli, S.A. and Modlin, R.L. (1995) CD1 and the expanding universe of T cell antigens.J. Immunol 155, 3709–10. (10.4049/jimmunol.155.8.3709) / J. Immunol by S.A. Porcelli (1995)
  62. Kuendig, T.M., Bachmann, M.F., DiPaolo, C. et al (1995) Fibroblasts as efficient antigen presenting cells in lymphoid organs.Science 268, 1343–7. (10.1126/science.7761853) / Science by T.M. Kuendig (1995)
  63. Zinkernagel, R. M. (1996) Immunology taught by viruses.Science 271, 173–8. (10.1126/science.271.5246.173) / Science by R. M. Zinkernagel (1996)
  64. Tarr, P.E., Lin, R. and Jones, T. C. (1996) Vaccine Adjuvancy, in section: Future uses. In M. Marty (ed.),Manual of GM-CSF, pp. 219–232. Oxford: Blackwell Science. / Manual of GM-CSF by P.E. Tarr (1996)
  65. Liehl, E., Hildebrandt, J., Lam, C. and Mayer, P. (1994) Prediction of the role of granulocyte-macrophage colony- stimulating factor in animals and man from in vivo results.Eur. J. Clin. Microbiol Infect. Dis. 13, Suppl 2, 9S-17S. (10.1007/BF01973596) / Eur. J. Clin. Microbiol Infect. Dis. by E. Liehl (1994)
  66. Tao, M.H. and Levy, R. (1993) Idiotype/granulocyte-macro- phage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.Nature 362, 755–8. (10.1038/362755a0) / Nature by M.H. Tao (1993)
  67. Loibner, H., Janzek, E., Mayer, P. and Liehl, E. (1995) Vaccination of rhesus monkeys with an anti-idiotype antibody mimicking Lewis Y: enhancement of the anti-tumor response by repeated administration of recombinant human GM-CSF. In Abstr. 10th Int. Conf. on monoclonal antibody immunoconjugates for cancer (abstr. 20). InAntibody Immunoconjugates Radiopharmaceut. 8, 64. / Antibody Immunoconjugates Radiopharmaceut. by H. Loibner (1995)
  68. Hansen, P.B., Johnson, H.E. and Kippe, E. (1993) Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor.Eur. J. Haematol. 50, 183–4. (10.1111/j.1600-0609.1993.tb00090.x) / Eur. J. Haematol. by P.B. Hansen (1993)
  69. Nathan, F. E. and Besa, E. C. (1992) GM-CSF and accelerated hemolysis.N. Engl J. Med. 326, 417. / N. Engl J. Med. by F. E. Nathan (1992)
  70. Dranoff, G., Jaffee, E., Lazenby, A. et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting anti-tumor immunity.Proc. Natl Acad. Sci. USA 90, 3539–43. (10.1073/pnas.90.8.3539) / Proc. Natl Acad. Sci. USA by G. Dranoff (1993)
  71. Sanda, M.G., Ayyagari, S.R., Jaffee, E.M. et al (1994) Demonstration of a rational strategy for human prostate cancer gene therapy.J. Urol 151, 622–8. (10.1016/S0022-5347(17)35032-2) / J. Urol by M.G. Sanda (1994)
  72. Berns, A.J.M., Clift, S., Cohen, L. K. et al (1995) Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma.Hum. Gene Ther. 6, 347–68. (10.1089/hum.1995.6.3-347) / Hum. Gene Ther. by A.J.M. Berns (1995)
  73. Levitsky, H.I., Montgomery, J., Ahmadzadeh, M. et al (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduce, but not B7-1 transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.J. Immunol 156, 3858–65. (10.4049/jimmunol.156.10.3858) / J. Immunol by H.I. Levitsky (1996)
  74. Meeker, T., Lowder, J., Clearly, M. L. et al (1985) Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies.N. Engl J. Med. 312, 1658–65. (10.1056/NEJM198506273122602) / N. Engl J. Med. by T. Meeker (1985)
  75. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. and Stern, P. L. (1993) Natural history of HLA expression during tumor development.Immunol. Today 14, 491–9. (10.1016/0167-5699(93)90264-L) / Immunol. Today by F. Garrido (1993)
  76. Wu, T.C., Huang, A.Y.C., Jaffee, E.M., Levitsky, H.I. and Pardoll, D.M. (1995) A reassessment of the role of B7-1 expression in tumor rejection.J. Exp. Med. 182, 1415–21. (10.1084/jem.182.5.1415) / J. Exp. Med. by T.C. Wu (1995)
  77. Bevan, MJ. (1995) Antigen presentation to cytotoxic T lymphocytesin vivo.J. Exp. Med. 182, 639–41. (10.1084/jem.182.3.639) / J. Exp. Med. by MJ. Bevan (1995)
  78. Suto, R. and Srivastava, P.K. (1995) A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides.Science 269, 1585–8. (10.1126/science.7545313) / Science by R. Suto (1995)
  79. Falo, L.D., Kovacsovics-Bankowski, M., Thompson, K. and Rock, K. L. (1995) Targeting antigen into the phagocytic pathwayin vivo induces protective tumour immunity.Nature Med. 1, 649–53. (10.1038/nm0795-649) / Nature Med. by L.D. Falo (1995)
  80. Tan, K.C., Hosoi, J., Grabbe, S., Asahina, A. and Granstein, R. D. (1994) Epidermal cell presentation of tumor- associated antigens for induction of tolerance.J. Immunol. 153, 760–7. (10.4049/jimmunol.153.2.760) / J. Immunol. by K.C. Tan (1994)
  81. Grabbe, S., Beissert, S., Schwarz, T. and Granstein, R. D. (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?Immunol. Today 16, 117–21. (10.1016/0167-5699(95)80125-1) / Immunol. Today by S. Grabbe (1995)
  82. Hsu, F.J., Benike, C., Fagnoni, F. et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells.Nature Med. 2, 52–7. (10.1038/nm0196-52) / Nature Med. by F.J. Hsu (1996)
  83. Zitvogel, L., Mayordomo, J.I., Tjandrawan, T. et al. (1996) Therapy of murine tumors with tumor peptide pulsed dendritic cells: Dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines.J. Exp. Med. 183, 87–97. (10.1084/jem.183.1.87) / J. Exp. Med. by L. Zitvogel (1996)
  84. Celluzzi, CM., Mayordomo, J.I., Storkus, W.J., Lotze, M. T. and Falo, L. D. (1996) Peptide-pulsed dendritic cells induce antigen-specihc, CTL-mediated protective tumor immunity.J. Exp. Med. 183, 283–7. (10.1084/jem.183.1.283) / J. Exp. Med. by CM. Celluzzi (1996)
  85. Paglia, P., Chiodoni, C., Rodolfo, M. and Colombo, M. P. (1996) Murine dendritic cells loadedin vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigenin vivo.J. Exp. Med. 183, 317–322. (10.1084/jem.183.1.317) / J. Exp. Med. by P. Paglia (1996)
  86. Young, J. W. and Inaba, K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.J. Exp. Med. 183, 7–11. (10.1084/jem.183.1.7) / J. Exp. Med. by J. W. Young (1996)
  87. Mosmann, T. R. and Coffman, R.L. (1989) Thl and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties.Ann. Rev. Immunol. 7, 145–73. (10.1146/annurev.iy.07.040189.001045) / Ann. Rev. Immunol. by T. R. Mosmann (1989)
  88. Paul, W.E. and Seder, R.A. (1994) Lymphocyte responses and cytokines.Cell 76, 241–51. (10.1016/0092-8674(94)90332-8) / Cell by W.E. Paul (1994)
  89. Katz, J.D., Benoist, C. and Mathis, D. (1995) T helper subsets in insulin dependent diabetes.Science 268, 1185–8. (10.1126/science.7761837) / Science by J.D. Katz (1995)
  90. Hsieh, C.S., Macatortia, S.E., Tripp, C.S., Wolf, S.F.,O’Garra, A. and Murphy, K.M. (1993) Development of Thl CD4+ T cells through IL-12 produced by Listeria induced macrophages.Science 260, 547–9. (10.1126/science.8097338) / Science by C.S. Hsieh (1993)
  91. Kuchroo, V.K., Das, M.P., Brown, J.A. et al. (1995) B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 development pathways: Application to autoimmune disease therapy.Cell 80, 707–18. (10.1016/0092-8674(95)90349-6) / Cell by V.K. Kuchroo (1995)
  92. Freeman, G.J., Boussiotis, V.A., Anumanthan, A. et al. (1995) B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.Immunity 2, 523–32. (10.1016/1074-7613(95)90032-2) / Immunity by G.J. Freeman (1995)
  93. Maurer, D. and Stingl, G. (1996) Wound healing, in: section future uses. In M. Marty (ed.),Manual of GM-CSF, pp. 208–18, Oxford: Blackwell Scientific. / Manual of GM-CSF by D. Maurer (1996)
  94. Lin, R., Tarr, P.E. and Jones, T.C. (1995) Present status of the use of cytokines as adjuvants to protect with vaccines against infectious diseases.Clin. Inf. Dis. 21, 1439–49. (10.1093/clinids/21.6.1439) / Clin. Inf. Dis. by R. Lin (1995)
  95. Lin, R., Tarr, P.E. and Jones, T.C. (1996) Considerations regarding the use of cytokines in active specific immunotherapy of cancer.Vac. Res. 5, 41–51. / Vac. Res. by R. Lin (1996)
  96. Lenardo, M.J. (1991) Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis.Nature 353, 858–61. (10.1038/353858a0) / Nature by M.J. Lenardo (1991)
  97. Huang, Y.P., Pechere, J.C, Michel, M. et al. (1992)In vivo T cell activation,in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women.J. Immunol. 148, 715–22. (10.4049/jimmunol.148.3.715) / J. Immunol. by Y.P. Huang (1992)
  98. Afonso, L.C.C., Scharton, T.M., Vieira, L.Q., Wysocka, M., Trinchieri, G. and Scott, P. (1994) The adjuvant effect of interleukin-12 in a vaccine againstLeishmania major.Science 263, 235–7. (10.1126/science.7904381) / Science by L.C.C. Afonso (1994)
  99. Adachi, T., Motojima, S., Hirata, A., Fukuda, T. and Makino, S. (1995) Eosinophil viability enhancing activity in sputum from patients with bronchial asthma: Contributions of interleukin-5 and granulocyte-macrophage colony- stimulating factor.Am. J. Respir. Crit. Care Med. 151, 618–23. / Am. J. Respir. Crit. Care Med. by T. Adachi (1995)
  100. Frandji, P., Tcaczyk, C, Oskeritzian, C. et al. (1995) Presentation of soluble antigens by mast cells: Upregulation by interleukin-4 and granulocyte-macrophage colony-stimulating factor and downregulation by interferon-γ.Cell Immunol. 163, 37–46. (10.1006/cimm.1995.1096) / Cell Immunol. by P. Frandji (1995)
  101. Bratton, D.L., Hamid, Q., Boguniewicz, M., Doherty, D.E., Kaliey, J.M. and Leung, D.Y.M. (1995) Granulocyte-macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis.J. Clin. Invest. 95, 211–8. (10.1172/JCI117642) / J. Clin. Invest. by D.L. Bratton (1995)
Dates
Type When
Created 16 years, 9 months ago (Nov. 18, 2008, 7 a.m.)
Deposited 2 years, 3 months ago (May 21, 2023, 12:03 a.m.)
Indexed 2 months, 3 weeks ago (June 10, 2025, 1:49 p.m.)
Issued 29 years ago (Sept. 1, 1996)
Published 29 years ago (Sept. 1, 1996)
Published Print 29 years ago (Sept. 1, 1996)
Funders 0

None

@article{Tarr_1996, title={Granulocyte-macrophage colony-stimulating factor and the immune system}, volume={13}, ISSN={1559-131X}, url={http://dx.doi.org/10.1007/bf02990841}, DOI={10.1007/bf02990841}, number={3}, journal={Medical Oncology}, publisher={Springer Science and Business Media LLC}, author={Tarr, Philip E.}, year={1996}, month=sep, pages={133–140} }